Sanofi

News

Look out Dupixent, Lilly's lebrikizumab is on the march

Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner.

News

Sanofi extends its Pompe range with first Nexviazyme OK

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder.

News

Sanofi and Regeneron eye Libtayo challenge to Keytruda in fi...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe conte

News

Sanofi swoops on partner Translate, buying the mRNA firm for...

Sanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together in 2018, and has now gone all in, offering $3.2 billion to buy the compan

News

FDA okays Viatris' insulin drug as first 'interchangeable' b...

Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sano

News

Pfizer puts up $1bn to buy into Arvinas breast cancer progra...

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells' natural protein-denaturing machin

Look out Dupixent, Lilly's lebrikizumab is on the march

Sanofi extends its Pompe range with first Nexviazyme OK

Sanofi and Regeneron eye Libtayo challenge to Keytruda in fi...

Sanofi swoops on partner Translate, buying the mRNA firm for...

FDA okays Viatris' insulin drug as first 'interchangeable' b...

Pfizer puts up $1bn to buy into Arvinas breast cancer progra...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Sanofi

Editor's Picks